I initiated coverage on Pfizer (NYSE: PFE ) stock with a "Buy" rating, stating that the company's low valuation and strong product pipeline make it the ultimate buying opportunity for income investors in the healthcare sector. In early May, IHe leads the investing group Beyond the Wall Investing with features that include: a fundamentals-based portfolio, weekly analysis on insights from institutional investors, regular alerts for short-term trade ideas based on technical signals, ticker feedback by request ...

At an investor summit in New York on Tuesday, activist investor Starboard called out Pfizer's (PFE) board of directors to take action against the latter’s management for making poor capital allocation, research and development (R&D) failures and problems with forecasting and budgeting.Per Starboard, these decisions have resulted in Pfizer losing nearly $20-$60 billion of market value since 2019, despite receiving a $40 billion boost from its COVID-19 franchise during the pandemic.This is the first time that ...

Pfizer Inc. (PFE) announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 18-59 years who are at increased risk of the disease. Following the latest FDA nod, Abrysvo has become the first and only RSV vaccine approved for adults who are younger than 50 years. Abrysvo is currently approved for t ...

Pfizer (PFE) will report its third-quarter 2024 earnings on Oct. 29, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.19 billion and 64 cents per share, respectively. Pfizer’s 2024 earnings estimates have risen from $2.62 to $2.66 per share over the past 30 days. For 2025, earnings estimates have been stable at $2.85 per share over the same timeframe.PFE Estimate MovementImage Source: Zacks Investment ResearchPFE’s Earnings Surprise HistoryThe healthcare bellwether’s ...

Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.Pharmaceutical giant Pfizer (PFE -0.31%) has long been a player in the healthcare industry, but it's currently experiencing a bit of a hangover. Pfizer's business rapidly expanded during the COVID-19 pandemic, thanks to a temporary growth spurt from selling Comirnaty (its COVID-19 vaccine) and Paxlovid (its antiviral therapy for COVID-19).But those sales have fallen dramatically as pandemic pressur ...

Drug giant Pfizer (PFE) is trading quite cheap after its stock took a beating last year once the pandemic ended. The stock is trading at a discount to the industry and is also trading below its 5-year mean. Going by the price/earnings ratio, the company's shares are currently trading at 10.25 forward earnings, lower than 19.08 for the industry and the stock’s 5-year mean of 11.37.Image Source: Zacks Investment ResearchIf you consider the price/sales ratio, its forward sales multiple of 2.63 is lower than it ...

Activist investor Starboard Value has sharpened its criticism of Pfizer Inc. PFE, holding the pharmaceutical giant’s management accountable for failing to deliver on its promises of innovation and growth.Despite its relatively small stake in Pfizer, Starboard’s critique reflects broader investor frustration with the company’s stock, which has dropped about 50% since 2021.During the Active-Passive Investor Summit, Starboard argued that Pfizer’s leadership, under CEO Albert Bourla, has not fully capitalized o ...

Activist hedge fund Starboard has taken a stake in drug giant Pfizer.Starboard execs met with company officials last week to outline their complaints.See highlights from the 74-page slideshow Starboard presented to Pfizer at the meeting. Sign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Read preview Thanks for signing up! Go to newsletter preferences Thanks for signing up! Access your favorite topics in a personalized feed while you're on ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Pfizer (PFE) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 29. On ...

Hedge funds managed by Israel Englander and Ken Griffin both scooped up shares in a troubled pharmaceutical stock last quarter.Each quarter, investment firms managing over $100 million are required to file a form 13F with the Securities and Exchange Commission (SEC). These filings provide valuable insight into which stocks the "smart money" investors on Wall Street are buying and selling.Last quarter, Ken Griffin's Citadel and Israel Englander's Millennium Management both bought Pfizer (PFE -0.90%) stock. I ...